No abstract

No abstract

No abstract

No abstract

time frame, with a focus on patients with pre-existing lung fibrosis and/or lung function compromise. This patient group is known to have a poorer survival outcome with conventional radiotherapy due to worsening of their pre existing lung condition. This study was aimed at generating real world data of SABR outomes in this population. Method: Data about staging, pathology, lung function, treatment response and follow up in primary early stage lung cancer patients treated with SABR at a tertiary cancer center over a 4 year time frame was gathered retrospectively and analysed for outcomes in survival differences between patients with compromised and non compromised lung function. For the purpose of this abstract compromised lung function was defined as clinical/radiological diagnosis of pulmonary fibrosis and/or a transfer factor for carbon monoxide (TLCO) <40% predicted. Result: The records of 274 patients with a median age of 78 years were analysed. 50(18.2%) patients were found to have compromised lung function as defined. 53% had MRC dypsnoea scores of 3 and 75% were current or ex smokers. 80% of the patients had moderate to severe comorbidity. Median overall survival estimate by Kaplan Meir method for patients with compromised lung function undergoing SBRT was 31.9 months(95% CI 22.3-41.5) was not significantly different from patients without compromised lung function 32.0 months (95% CI 27.1-37.0) p¼0.552. Conclusion: SBRT for primary lung cancer appears to be as safe in patients with compromised lung function as those without.